MMSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Merit Medical Systems Inc (MMSI) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the company has shown strong financial growth in its latest quarter and maintains a stable competitive position, the lack of clear catalysts, bearish technical indicators, and mixed analyst sentiment suggest that it is better to wait for a more favorable entry point.
The MACD is positive and expanding, indicating potential bullish momentum. However, the RSI is neutral at 51.79, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 68.79, with resistance at 70.656 and support at 66.924, suggesting limited immediate upside.
Strong financial performance in Q4 2025, with revenue up 10.92% YoY, net income up 35.99% YoY, and EPS up 36.96% YoY. The company's oncology portfolio expansion via the View Point Medical acquisition could drive future growth.
Mixed analyst sentiment with recent downgrades citing guidance uncertainty and lack of growth catalysts. Bearish technical indicators and no significant hedge fund or insider trading trends. No recent news or congress trading data to act as a positive catalyst.
In Q4 2025, Merit Medical reported revenue of $393.936M (+10.92% YoY), net income of $38.006M (+35.99% YoY), EPS of $0.63 (+36.96% YoY), and gross margin of 49.59% (+1.81% YoY). These figures indicate strong growth and profitability improvements.
Analyst sentiment is mixed. Canaccord maintains a Buy rating with a reduced price target of $90. Wells Fargo downgraded the stock to Equal Weight with a reduced price target of $78, citing guidance uncertainty and lack of catalysts. Barrington and Baird maintain Outperform ratings with price targets of $109 and $104, respectively, while Piper Sandler and BTIG also see potential upside but have lowered their targets.
